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Abstract
Background: In recent years, there have been numerous calls for global institutions to develop and enforce new
international laws. International laws are, however, often blunt instruments with many uncertain benefits, costs, risks
of harm, and trade-offs. Thus, they are probably not always appropriate solutions to global health challenges. Given
these uncertainties and international law’s potential importance for improving global health, the paucity of
synthesized evidence addressing whether international laws achieve their intended effects or whether they
are superior in comparison to other approaches is problematic.
Methods: Ten electronic bibliographic databases were searched using predefined search strategies, including
MEDLINE, Global Health, CINAHL, Applied Social Sciences Index and Abstracts, Dissertations and Theses, International
Bibliography of Social Sciences, International Political Science Abstracts, Social Sciences Abstracts, Social Sciences
Citation Index, PAIS International, and Worldwide Political Science Abstracts. Two reviewers will independently
screen titles and abstracts using predefined inclusion criteria. Pairs of reviewers will then independently screen
the full-text of articles for inclusion using predefined inclusion criteria and then independently extract data
and assess risk of bias for included studies. Where feasible, results will be pooled through subgroup analyses,
meta-analyses, and meta-regression techniques.
Discussion: The findings of this review will contribute to a better understanding of the expected benefits
and possible harms of using international law to address different kinds of problems, thereby providing
important evidence-informed guidance on when and how it can be effectively introduced and implemented
by countries and global institutions.
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Background
In recent years, there have been numerous calls for global
institutions to develop and enforce new international laws
in the realm of health. These international laws, which
regulate relations between and within countries, vary
widely in their subject matter. Focus areas for these calls
have included alcohol [1], antimicrobial resistance [2–10],
chronic diseases [11], falsified/substandard medicines [12],
health system corruption [13], impact evaluations [14],
nutrition [15], obesity [16], research and development
[17, 18], and global health broadly [19]. Various stake-
holders, including individual experts and intergovernmen-
tal organizations, have prompted these calls for new
international treaties. Commonly cited evidence to sup-
port these proposals are past “successful” global health
laws, including the World Health Organization’s Frame-
work Convention on Tobacco Control (2003) and the Inter-
national Health Regulations (2005) [20].
Although few international laws have been adopted
specifically to promote human health, many inter-
national laws have possible indirect effects on health, as
they may impact the social determinants of health (i.e.,
the external conditions in which people live that may
affect their health). Examples of social determinants of
health include armed conflict, employment, empower-
ment, environment, finance, human rights, poverty, sani-
tation, social policies, trade, and water supply [21, 22].
One prominent example of such an international law is
the World Trade Organization’s Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS).
This law serves as the de facto global regulating policy
for all forms of intellectual property, including copy-
rights, patents, and trademarks. The rules set out by this
agreement have major implications for the medical
product industry and thereby influence global access to
medicines [23, 24].
While many stakeholders have advocated for inter-
national laws that provide solutions to complex global
health challenges [1–19], others have raised concerns
about international law being a blunt instrument with
many uncertain benefits, costs, risks of harm, and
trade-offs [25–30]. Few calls for new laws fully consider
their potentially coercive and potentially paternalistic
nature or the direct costs associated with drafting, rati-
fication, and enforcement, including numerous meet-
ings, legal fees, and duplicative governance structures
that must be supported by governments. Further, the
indirect opportunity costs associated with the re-
sources, energy, and rhetorical space that go into nego-
tiating international laws and implementing them may
draw attention away from other potentially more im-
portant initiatives [25–30].
Given these uncertainties associated with international
law, and its ever-increasing popularity as a potential tool
for global change, there is surprisingly little synthesized
evidence on whether international laws achieve their
intended results or whether they are superior to other
available instruments for coordinating international ac-
tors. The current lack of synthesized evidence on the
effectiveness of international law has posed a significant
barrier to understanding the potential value, feasibility,
and applicability of international law for global health
and related challenges.
A scoping review by Hoffman and Røttingen (2015)
attempted to delineate the effects of international law by
qualitatively summarizing 90 quantitative impact evalua-
tions of different international laws [28]. That review,
which is the most comprehensive to date, found that the
effects of international laws were mixed and dependent
on the nature of the instrument, its intended outcome,
and mediating factors. While some international laws
may promote beneficial outcomes, this may not always
be the case. This recent review did not follow a system-
atic search or analysis protocol and was unable to pro-
duce a comprehensive analysis or an authoritative list of
considerations.
This planned systematic review will build on the ap-
proach and findings of that recent scoping review, apply-
ing subgroup analysis, meta-analysis, and meta-
regression techniques to synthesize all available quanti-
tative research evidence on the effects of international
law on health and its social determinants. Specifically,
this review aims to answer the following three questions:
(1) What are the effects of international law on health
behaviors and outcomes?
(2) What are the effects of international law on the
social determinants of health?
(3) Upon what factors are effects of international law
conditional?
For example, in the context of the Framework Conven-
tion on Tobacco Control (FCTC), which is a global health
treaty providing an internationally coordinated response
to combatting tobacco use [20], the review would aim to
identify:
(1) What are the effects of the FCTC on health
behaviors and outcomes like tobacco consumption,
lung cancer rates, and life expectancy?
(2) What are the effects of the FCTC on social
determinants of health like tobacco advertising
bans, tobacco taxes, and smoke-free workplace
policies?
(3) Upon what factors are the effects of the FCTC
conditional, such as a country’s development status,
regulatory capacity, and government ownership of
tobacco companies?
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This systematic review will boost current understand-
ing on whether and how countries and global institu-
tions might employ international law as a population




We will conduct this systematic review, meta-analysis,
and meta-regression adhering to the following protocol
and will report any changes to the protocol that arise as
we proceed. The methods and design of this systematic
review are based on recommendations from the Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA-P) statement [31]. See Additional file 1 for the
PRISMA-P 2015 checklist. The protocol is registered with
the PROSPERO international prospective register of sys-
tematic reviews (registration number CRD42015019830).
Types of study designs
All quantitative impact evaluations that measure the ef-
fect of an international law on outcomes related to
health or its social determinants will be included. These
may include experiments (e.g., randomized controlled
trials), quasi-experiments (e.g., interrupted time-series
analyses), and observational designs (e.g., pooled time-
series cross-sectional analyses, event histories, survival
analyses).
Types of participants
Given that international law only imposes obligations
on states (with only a small number of exceptions
such as crimes against humanity for which individuals
can also be convicted), “participants” will include all
current and former countries, formally recognized as
states by the international community, which is best
indicated by membership in the United Nations or a
similar multilateral organization. We will interpret
this definition broadly to include jurisdictions that are
often viewed as states by some entities (e.g., Monaco,
Palestine, Taiwan, Vatican City).
Types of interventions
Any implementation of international law related to
health or its social determinants between at least two
states will be considered as an intervention. Inter-
national law is commonly referred to as agreements,
charters, conventions, declarations, exchange of notes,
memorandums of understanding, modus vivendi, proto-
cols, treaties, and at least 30 other names. It is defined
as the “rules and principles of general application dealing
with the conduct of states and of international organiza-
tions and with their relations inter se, as well as with
some of their relations with persons” [32]. Randomized
controlled interventions are not necessary for studies to
meet eligibility for inclusion in this review. Examples of
possible control interventions include, but are not lim-
ited to, the absence of an international law or a local
state law.
Type of outcomes
To be included, a study has to measure the effect of
international law on an objective and quantifiable out-
come related to health or its social determinants,
which, according to the World Health Organization’s
Commission on the Social Determinants of Health
(2008), include armed conflict, employment, empower-
ment, environment, finance, human rights, poverty, sani-
tation, social policies, trade and water supply, and among
other factors [22]. Outcomes will be broadly categorized
as changes to people (e.g., health status), places (e.g., car-
bon emissions), products (e.g., availability of medicines), or
policies (e.g., new regulations or taxes). As this is an ex-
ploratory review, we have not specified exact outcomes a
priori and have no reason to believe that one outcome will
be more important than another. We will base the out-
comes upon what data is available in the set of included
studies and treat all outcomes as primary outcomes. How-
ever, we will preferentially extract and report outcomes
that are found to have more data.
Search strategy
The search strategy for this review was developed in con-
sultation with one health sciences librarian at McMaster
University and one at the University of Toronto. The
following ten electronic bibliographic databases were
searched from inception to July 2014: MEDLINE, Global
Health, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Applied Social Sciences Index and
Abstracts, International Bibliography of Social Sciences,
International Political Science Abstracts, Social Sciences
Abstracts, Social Sciences Citation Index, Public Affairs
Information Service International (PAIS International),
and Worldwide Political Science Abstracts. To find gray
literature, we also conducted an additional search in
ProQuest’s Dissertations and Theses electronic database.
No language, geography, or date restrictions were applied
to the searches.
The exact search conducted in MEDLINE is pre-
sented in Table 1. See Additional file 2 for a list of
the exact searches conducted in all ten electronic
bibliographic databases and the dissertations and
theses database.
Study selection
This systematic review will include any published or un-
published study that aims to quantitatively measure the
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impact of an international law’s effect on any health-
related behavior or outcome, including social determi-
nants of health [22]. Studies will be included if the an-
swer is “yes” to all of the following questions:
(1) Is the study a quantitative impact evaluation?
(2) Are the participants current or former countries?
(3) Is there an international law being discussed?
(4) Are the effects of an international law being
measured? (i.e., the effects on health and its social
determinants)
Two reviewers will independently evaluate titles and
abstracts to determine whether or not each article might
meet eligibility criteria. The initial title and abstract
screening process will make use of the aforementioned
four criteria to assess whether articles will be assessed
for inclusion at the full-text screening stage. For all stud-
ies included after title and abstract screening, four pairs
of reviewers will independently screen the full-text of ar-
ticles for inclusion, applying the same four criteria. A
codebook containing examples for all four inclusion cri-
teria will be developed to help guide reviewers through
the screening process. Prior to full-text screening, mul-
tiple rounds of calibration exercises will be conducted to
ensure that there is near-perfect consistency among re-
viewers. Each round of calibration will be followed by a
meeting with all reviewers to resolve any discrepancies.
All disagreements that arise during full-text screening
will be documented and resolved through discussion and
consensus; if consensus cannot be reached, the principal
investigator (SJH) will settle disagreements (Fig. 1).
Additional records found in the recent scoping review
[28] will go straight to full-text screening, bypassing title
and abstract screening, because they are very likely eli-
gible for inclusion.
Data management and extraction
Search results from all databases will be aggregated in
the reference management software EndNote, which will
also be used to remove duplicate citations.
A statistician has been contracted to aid in developing
the data abstraction form so as to ensure comprehensive
extraction methods that will allow for pooling and ana-
lysis of results. Additionally, calibration exercises will be
conducted to ensure that there is consistency between
reviewers. These exercises will serve to pretest the form
before it is used to extract data from eligible studies. An
online data abstraction program (Distiller SR) will be
used to maximize efficiency—it will be customized for
this task using the criteria of a standardized form. Two
pairs of reviewers will independently extract data from
each eligible study. Data extracted will include general
study information, methodology, intervention details,
and outcome data. Any disagreements will be docu-
mented and resolved through discussion and consensus;
when consensus cannot be reached, the principal investi-
gator will settle disagreements.
Risk of bias (quality) assessment
Studies that are consistent with the inclusion criteria will
be assessed for bias using Cochrane’s ROBINS-I tool for
non-randomized studies of interventions [33]. We do
not anticipate the inclusion of any relevant random-
ized trials given the nature of the intervention (i.e.,
randomizing countries to receive an international law
would not be politically feasible). Note that although
the kinds of biases are broadly equivalent for ran-
domized and non-randomized studies—namely selec-
tion, confounding, group equivalence, spill-overs, and
reporting biases—there are important differences in
their operationalization. Reviewers will resolve dis-
agreements by discussion and through consultation
with the principal investigator if necessary.
In presenting the evidence, the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) system of rating the quality of evidence will
be used, as recommended by the Cochrane Collabor-
ation [34].
Strategy for data synthesis
Three types of analyses are currently planned, resulting
in at least three sets of results: (1) point estimates and
confidence intervals for the impact of international laws
Table 1 Search terms used in Ovid MEDLINE
MEDLINE search
Citations yielded = 576
1. (law or laws or agreement* or treaty or treaties or convention* or
accord or accords or covenant* or protocol* or charter or charters or
regime* or cooperation* or legislation*).tw.
2. (international or global or multi?national or trans?national or foreign
or multi?lateral).tw.
3. (quantitative or empirical or experiment or experiments or
experimental or quasi-experiment or quasi-experiments or quasi-
experimental or statistic* or time?series or cross?sectional or tscs or
counterfactual or ANOVA or MANOVA or t-test or z-test or f-test or
logistic or correlation or frequentist or Bayesian or maximum
likelihood or least squares or parametric or covariance).tw.
4. (effect* or affect* or impact* or ratif* or difference or differences or
compliance or comply or adher* or implement* or influenc* or
impact* or chang* or measur* or constrain* or screen* or behavio?r
or deter* or reduc* or increas* or decreas* or inflat* or vary or
variation* or varie*).tw.
5. ((law or laws or agreement* or treaty or treaties or convention* or
accord or accords or covenant* or protocol* or charter or charters or
regime* or cooperation or legislation*) adj3 (international or global or
multi?national or trans?national or foreign or multi?lateral)).tw.
6. 3 and 4 and 5
Hoffman et al. Systematic Reviews  (2016) 5:64 Page 4 of 9
in each field on any outcome; (2) point estimates and
confidence intervals for the impact of international laws
from any field on particular outcomes; and (3) a list of
the conditions thus far found to potentially mediate the
impact of international laws. Meta-analysis will facilitate
the first two lines of inquiry, while meta-regression will
help answer the third.
Meta-analysis
In the earlier scoping review of 90 quantitative impact
evaluations [28], most studies were time-series cross-
sectional analyses that provided quantitative data on
continuous variables suitable for pooling. However,
the studies evaluated different international laws
across different countries, years, and outcome vari-
ables. In this review, we will determine the extent to
which it is plausible that effects are similar across the
range of the populations, the interventions, and the
outcomes; for questions in which it is plausible, we
will conduct meta-analyses.
In principle, our aim is to be liberal in this judg-
ment: that is, we are prepared to pool results from a
relatively broad range of populations, interventions,
and outcomes. Having done that, we can examine the
variability in results to determine the extent to which
the data support the assumption regarding similar ef-
fects across populations, interventions, and outcomes.
We anticipate substantial variability and will address
this through meta-regression analysis (see below).
Since we know that the studies will measure outcomes
of interest in different units, the effect size will be calcu-
lated using the difference in mean values divided by the
pooled standard deviation of the comparators (e.g., inter-
vention versus non-intervention group or standard
deviation before and after introduction of intervention).
This calculation will result in a measure of the effect
known as the standardized mean difference (SMD) (also
sometimes labeled the “effect size”). For each study, the
SMD is calculated as the difference in mean outcome
between groups divided by the standard deviation of
outcome among participants, as represented in the fol-
lowing equation:
SMD ¼ Difference in mean outcome between groups
Standard deviation of outcome among participants
The resulting standard deviations are used to
standardize the mean differences to a single scale, as
well as in the computation of study weights using the in-
verse variance method. This method assumes that
between-study variation in standard deviations reflects
only differences in measurement scales and not differ-
ences in the reliability of outcome measures or variabil-
ity among study populations [35].
The SMD from each study is pooled to provide a
summary measure in standard deviation units with an
associated confidence interval. Random effects meta-
analysis will be used, as this approach is conservative
in that it considers both within- and between-study
differences in calculating the error term. We will
examine the extent of heterogeneity statistically using
chi-square tests of heterogeneity and of inconsistency
using the I2 measure.
In interpreting the results, a rule of thumb suggests
that 0.2 standard deviation units represents a small
effect, 0.5 a moderate effect, and 0.8 a large effect. In
addition to this rule of thumb, to facilitate our inter-
pretation, we will convert the SMDs to measures of
effect typically used for binary outcomes. In principle,
Fig. 1 PRISMA flow diagram (in process). Legend:ASSIAApplied Social Sciences Index and Abstracts,CINAHLCumulative Index to Nursing and Allied
Health Literature,IBSSInternational Bibliography of Social Sciences,PAIS InternationalPublic Affairs Information Service International
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this approach assumes that data are normally distrib-
uted, allowing calculation of the probability that re-
sults are greater than equal to a particular threshold.
These probabilities allow calculation of odds ratios
and risk differences. There are a number of methods
available to conduct the conversion from continuous
to binary outcomes. We will use the approach de-
scribed by Furukawa [36].
Meta-regression analysis
Meta-regression analysis will be used to systematically
explore the reasons for different effect sizes and out-
comes across studies. Meta-regressions are similar to
standard regressions, in which an outcome variable is
predicted according to the values of one or more ex-
planatory variables. In meta-regression, the dependent
variable is the effect estimate (in this case, the SMD for
each study). The independent or explanatory variables
are characteristics of studies that might influence the
size of the intervention effect. In meta-regression, larger
studies have more influence on the relationship than
smaller studies, since studies are weighted by the preci-
sion of their respective effect estimate. We will use a
random-effects meta-regression in which the residual
heterogeneity among intervention effects not captured
by the independent explanatory variables is incorporated
in the same way as in a random effects meta-analysis.
The regression coefficients obtained from a meta-
regression analysis will describe how the outcome
variable (i.e., the intervention effect) changes with a
unit increase in the explanatory variable (i.e., the po-
tential effect modifier). The statistical significance of
the regression coefficient is a test of whether there is
a linear relationship between intervention effect and
the explanatory variable.
The meta-regression will allow us to test existing the-
ories in international law and international relations
about when law matters and to provide global policy-
makers with evidence-informed guidance on when dif-
ferent types of international laws may be most helpful
(and when they may even be harmful). Among inter-
national lawyers and international relations scholars, the
effectiveness of international law stands as a subject of
great debate. Elucidating the conditions upon which
international law has effects, and what these effects may
be, will allow for a strengthened understanding of the
way in which international law works.
Specifically, informed by a new analytic framework we
have developed [28, 37], we will examine the following a
priori specified possible determinants of heterogeneity,
including postulated directions of effect. Based on find-
ings from the recent scoping review’s assessment of
international laws’ effects [28], we hypothesize larger
and more beneficial effects in international laws that
deregulate rather than regulate activity, international
laws that target countries’ foreign rather than domestic
policies, international laws that target low- and middle-
income countries rather than high-income countries,
international laws assessed in the last decade versus
prior decades, and international laws adopted to im-
prove national security or the economy rather than so-
cial well-being or the environment [28]. In addition, we
will explore the possible impact of study design on mag-
nitude of effect. The study designs included in this re-
gression will include cross-sectional studies, time-series
studies of individual jurisdictions, and time-series studies
of multiple jurisdictions.
In the absence of direct evidence, the aforementioned
analytic framework outlines four criteria intended to
assist decision-makers to ensure that new international
laws are likely to yield positive effects. It takes into
account the uncertain benefits, costs, risks of harm,
and trade-offs involved with the implementation of
international law. Specifically, the four criteria for
assessing international laws are as follows: (1) there
must be a significant transnational dimension to the ad-
dressed problem; (2) the coercive nature of treaties
should be justified by the goals of the proposed solu-
tion; (3) there must be a reasonable likelihood that the
treaty will achieve benefits; and (4) the treaty should
represent the best commitment mechanism among
competing alternatives [23]. This systematic review will
be used to test these criteria and update the analytic
framework.
Additional analyses of subgroups
In addition to the meta-regression, we will also do more
traditional subgroup analyses. These analyses are cur-
rently planned for the following attributes to ascertain
effects of different types of international laws under dif-
ferent circumstances:
a. By policy domain: Analysis across policy domain
of international laws such as environment,
finance, health, human rights, humanitarianism,
and trade will allow for comparison of magnitude
of effects of laws operating in different areas of
intervention.
b. By enforcement mechanism: Level or robustness of
enforcement mechanisms embedded in treaties or
used by states to encourage compliance such as legal
penalties, monetary fines, and “naming and shaming”
may impact the magnitude of its effects.
c. By impact/indicator measure: Categorization of
studies by impact measures such as economic
growth, health status, and trade flows allows for
comparison of the effects of international treaties on
the same indicators.
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d. By scope of the intervention: This may provide
insight into the relationship between the number of
countries that are party to an international law and
the impact measured on outcomes, such as between
an international law binding a small group of
countries versus a law adopted through the United
Nations which may have almost 200 state parties.
e. By study design: Robustness of analytical methods
may impact the magnitude of effects determined in
each study, and categorization by study design will
be necessary when we attempt to pool results.
f. By time period: This may give insight into whether
there was enough time to measure an impact and
whether international laws adopted at different time
periods might have been more successful.
g. By forum: This may provide information on whether
international laws have differing effects depending
on the process through which they are created
and the organization that may have hosted its
negotiation and enforcement, such as the United
Nations General Assembly, World Health
Organization, and World Trade Organization,
or without a formal organization.
Discussion
This review will use a rigorous systematic methodology
and will represent a novel attempt at investigating an
important question that has not yet benefitted from sys-
tematic synthesis techniques. While the review will build
on a recent scoping review [28], it is unlike that previous
study in that this planned review: (1) follows a system-
atic protocol for searching studies, assessing their rele-
vance, extracting information, and summarizing and
reporting it; (2) includes more and different types of in-
formation (e.g., measure of extent of impact); (3) will use
meta-analysis, allowing for the calculation of point esti-
mates and confidence intervals for the effects of past
international laws and some factors that influence ef-
fects’ direction and depth of impact; and (4) will use
meta-regression techniques to systematically draw les-
sons across international laws, including identifying im-
plementation considerations that influence why some
laws may have achieved positive impacts while others
did not. By strengthening and extending the method-
ology of the previous scoping review, this systematic re-
view will be more informative and allow for more
precise and unbiased results, thereby facilitating more
valuable insights and authoritative conclusions.
This systematic review has several strengths. First, it
addresses a particularly salient policy problem, as there
exists a widespread and active discussion on the devel-
opment of new global health laws [38, 39]. These pro-
posed laws have the potential to be beneficial, costly,
and/or harmful [37]. This review will help to inform
future decisions by identifying what types of inter-
national laws produce beneficial effects and under what
circumstances. Second, this review follows a systematic
and transparent protocol. We will employ recom-
mended and validated methods at all stages of the re-
view, ensuring that the review meets the standards of
either, or both, the Cochrane Collaboration’s Public
Health Group or the Campbell Collaboration’s Inter-
national Development Group. Another notable strength
is that the scope of the systematic review will be inclu-
sive and comprehensive as we will include gray litera-
ture such as dissertations and theses.
An important limitation of the study is its breadth of
potential outcomes; the review is very broad, includes
many studies, and considers a wide range of factors in-
fluenced by international laws. Our application of meta-
analysis and meta-regression techniques to these diverse
studies and outcomes may be affected by the significant
heterogeneity among the pool of eligible studies. This
may pose a challenge in comparing the success of differ-
ent international laws across outcomes as there is much
expected heterogeneity between the effects of the laws
included. However, our calculation of effect size using
SMD will allow us to pool results across different units.
Our rigorous approach for measuring heterogeneity will
ensure that we only pool results where feasible and ap-
propriate; for example, heterogeneity will be measured
prior to meta-analysis. Further, we will continue to have
ongoing discussions with statisticians to plan for an effi-
cient and optimal abstraction process in which we col-
lect data that will demonstrate meaningful results.
Another important limitation is that while our review in-
cludes theses and dissertations, we may have overlooked
studies that were not indexed such as government docu-
ments or civil society reports.
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